Business
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (\"NeuroSense\"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset, PrimeC.\n Health Canada Pre-NDS Meeting A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026.The decision was made to allow for the inclusion of additional emerging clinical, biomarker and survival data and analyses in the briefing package, which the Company believes will meaningfully strengthen the scientific and clinical foundation supporting PrimeC.The Company remains focused on advancing PrimeC under the NOC/c pathway in Canada, which is designed to facilitate earlier access to promising therapies addressing serious unmet medical needs.Alzheimer's Disease Program UpdateThe Company expects to report clinical and biomarker results from its Alzheimer's study in the coming weeks.Continued Momentum Across Key ProgramsNeuroSense continues to advance its clinical and regulatory strategy for PrimeC, supported by our previously disclosed:Statistically significant survival benefit (65% reduction in risk of death)Expanding biomarker dataset supporting multi-mechanistic activityFDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS\"As we generated additional valuable data, we believe it is strategic to incorporate these findings and analyses into our regulatory interactions,\" said Alon Ben-Noon, Chief Executive Officer of NeuroSense. \"Our objective is to present the most comprehensive and robust dataset possible to Health Canada, thereby maximizing the likelihood of a constructive and efficient regulatory pathway. We believe this approach positions the Company ahead of several important value inflection points across its ALS and Alzheimer's programs expected in 2026.\"About NeuroSenseNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet...